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Introduction: The impact of esophageal tumor length on pT1 esophageal adenocarcinoma has not been well
evaluated.
Methods: Case histories of all patients (n ¼ 133) undergoing esophageal resection from 1979 to 2007 with pT1
adenocarcinoma of the esophagus were reviewed. Univariate and multivariate analyses of esophageal tumor
length and other standard prognostic factors were performed.
Results: Patients with early-stage pT1 esophageal adenocarcinoma with tumors less than 3 cm demonstrate de-
creased long-term survival (3 years:>3 cm¼ 46% vs 93%; P<.001) and higher risk of lymph node involvement
(lymph node positive:>3 cm ¼ 47% vs 10%; P< .001). Multivariable analysis shows that esophageal tumor
length (>3 cm) is an independent risk factor for survival in patients with pT1 early-stage esophageal cancer (haz-
ard ratio: 4.8, 95% confidence intervals: 1.4–16.5; P<.001) even when controlled for submucosal involvement,
lymph node involvement, and lymphatic/vascular invasion status. In combination with submucosal involvement,
esophageal tumor length (>3 cm) identifies a high-risk population of pT1 esophageal adenocarcinoma (3 years:
group 1 [0 risk factors] ¼ 100%, group 2 [1 risk factor] ¼ 87%, and group 3 [2 risk factors] ¼ 33%; P< .001).
Conclusions: This study demonstrates that esophageal tumor length (>3 cm) is a risk factor for long-term sur-
vival and lymph node involvement in early-stage pT1 esophageal adenocarcinoma. Esophageal tumor length
(>3 cm) in combination with submucosal involvement may help to identify a high-risk group of patients with
pT1 esophageal adenocarcinoma.In esophageal cancer the T classification for esophageal car-
cinoma is currently based solely on tumor depth.1 Several au-
thors have found tumor length to be a significant factor in
predicting survival for patients with esophageal cancer.2-6
We have also observed that tumor length (>3 cm) appears
to be an important factor in patients with predominantly
more advanced nonmetastatic esophageal cancer.7 The po-
tential impact that tumor length (>3 cm) has on patients
with earlier pT1 adenocarcinoma of the esophagus has not
been well studied.
From the Departments of Thoracic and Cardiovascular Surgery,a Gastrointestinal
Medical Oncology,b Diagnostic Radiology,c Gastrointestinal Medicine and Nutri-
tion,d Radiation Oncology,e and Pathology,f The University of Texas M. D. Ander-
son Cancer Center, Houston, Tex.
This work was supported by the Homer Flower Gene Therapy Research Fund, the
Charles Rogers Gene Therapy Fund, the Flora & Stuart Mason Lung Cancer
Research Fund, the Charles B. Swank Memorial Fund for Esophageal Cancer
Research, the George O. Sweeney Fund for Esophageal Cancer Research, the Pha-
lan Thoracic Gene Therapy Fund, and theM.W. Elkins Endowed Fund for Thoracic
Surgical Oncology.
Received for publication May 9, 2008; revisions received Jan 16, 2009; accepted for
publication Feb 2, 2009; available ahead of print April 10, 2009.
Address for reprints: Stephen G. Swisher, MD, The University of Texas M. D. Ander-
son Cancer Center, Department of Thoracic and Cardiovascular Surgery, 1515 Hol-
combe Blvd, Box 445, Houston, TX 77030 (E-mail: sswisher@mdanderson.org).
J Thorac Cardiovasc Surg 2009;138:831-6
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2009.02.003The Journal of Thoracic and CIn this study, we therefore evaluate the importance of our
previously determined tumor length (>3 cm) in patients with
pT1 adenocarcinoma of the esophagus to determine whether
this factor is also able to help predict the risk of lymph node
involvement and long-term survival in patients with earlier
stage esophageal adenocarcinoma.
METHODS AND PATIENTS
Study Population
Data were obtained from the prospectively collected esophageal data-
base of the Department of Thoracic and Cardiovascular Surgery at the Uni-
versity of Texas M. D. Anderson Cancer Center (MDACC). The database
was reviewed from 1979 to 2007. A total of 1483 patients had surgical re-
section for esophageal cancer. All patients underwent surgical management
without preoperative chemotherapy or radiation. Patients with histologic
features other than adenocarcinoma (n ¼ 480) were excluded. Patients
with tumors having a T classification other than pT1 (n ¼ 781) or patients
who had chemotherapy or radiation therapy before surgery (n ¼ 84) were
excluded. Other exclusion criteria included patients who had an emergency,
salvage, or redo operation or those who did not undergo a curative operation
(n ¼ 2). Those patients who died perioperatively (n ¼ 3) were excluded so
that we could evaluate only the long-term impact of tumor-related factors
and not the short-term effect of perioperative death. Perioperative deaths
were defined as death during admission or death within 30 days of surgery.
There was no relationship with perioperative mortality and tumor length or
submucosal involvement. This left our study population at 133 patients. The
Institutional Review Board at The University of Texas MDACC approved
this study.ardiovascular Surgery c Volume 138, Number 4 831
General Thoracic Surgery Bolton et al
G
T
SAbbreviations and Acronyms
CI ¼ confidence intervals
CT ¼ computed tomography
HR ¼ hazard ratio
LVI ¼ lymphatic/vascular invasion
MDACC ¼ M. D. Anderson Cancer Center
PET ¼ positron emission tomography
Acquisition of Data
Preoperative staging was assessed by endoscopy, computed tomography
(CT), positron emission tomography (PET), PET-CT scans, endoscopic
ultrasound, fine needle aspirations, and staging laparoscopy as available
for the time period. Patients underwent an Ivor Lewis esophagectomy,
a transhiatal esophagectomy, a three-field esophagectomy, or a minimally
invasive esophagectomy per discretion of the surgeon and patient desires.
Pathologic staging of the tumor was performed using standard guidelines
and the American Joint Commission for Cancer esophageal cancer staging
system.1 Esophageal tumor length was determined by pathologic evaluation
in all cases.
Definition of Risk Factor Groups
Patients were divided into two groups on the basis of tumor length: one
group comprised patients with tumors greater than 3 cm in length and the
second group comprised patients with tumors 3 cm in length or shorter. A
cutoff value of 3 cm was used in this study because of our group’s previous
study in patients with more advanced tumors and an effort to determine
whether this cutoff would also be applicable in earlier stage tumors.7
We also added esophageal tumor length to submucosal involvement,
which is a previously recognized risk factor,8,9 to see whether we could
identify a high-risk group of patients with pT1 esophageal adenocarcinoma.
Patients with tumors 3 cm in length or less and with no submucosal involve-
ment were classified as group 1. Patients with tumors that were either more
than 3 cm in length or that had submucosal involvement, but not both, were
classified as group 2. Patients with tumors that were both more than 3 cm in
length and had submucosal involvement were classified as group 3.
Statistical Analysis
The Kaplan–Meier method was used to estimate survival curves. The
definition of survival was determined from the date of surgery and the
last known follow-up or date of death. Perioperative deaths were excluded
so that long-term survival owing to tumor-related factors and not short-term
outcomes could be assessed. The Pearson c2 and Fisher exact tests were
used to analyze significance where appropriate. Univariable Cox propor-
tional hazards regression model was used to examine the association be-
tween various prognostic predictors and survival (Table 1). Univariate
factors with a P value of<.25 and believed to be associated with cancer-re-
lated deaths were entered into a multivariable Cox proportional hazards re-
gression model. Using the Wald stepwise selection with P ¼ .10 as entry
and removal probability, we obtained the final model for the data set. The
statistical calculations were performed with the SPSS Software for Win-
dows (version 15; SPSS, Inc, Chicago, Ill) and GraphPad Prism (version
5; Invitrogen, Carlsbad, Calif).
RESULTS
Patient Characteristics
The total number of patients in this analysis was 133. The
median follow-up was 42 months. Table 2 summarizes the
patient demographics showing a predominantly white832 The Journal of Thoracic and Cardiovascular Su(93%), male (89%) population with the most common tu-
mor location in the lower esophagus (92%). The median
age was 63 years. Table 3 summarizes the pathologic tumor
factors demonstrating a similar number of patients with
(52%) and without submucosal involvement (48%). Most
patients were node negative (86%) and did not have lym-
phatic/vascular invasion (LVI) on pathologic examination
(77%). There were 118 patients with a tumor length of 3
cm or less and 15 patients with tumors greater than 3 cm
in length. Themedian tumor length was 1.34 cm. The overall
distribution of tumor length is demonstrated in Figure 1.
Analysis by Tumor Length
Survival was significantly improved in patients with
shorter tumors when assessed in a continuous fashion (P<
.001, hazard ratio [HR] ¼ 1.51, confidence interval [CI] ¼
1.22–1.87). A cutoff value of 3 cm was used in this study
in an effort to determine whether this cutoff would be appli-
cable in pT1 esophageal adenocarcinoma as well as more ad-
vanced tumors.7 Initial exploratory analyses in patients with
pT1 esophageal adenocarcinoma suggested that this cutoff
might also be significant inasmuch as a significant decrease
in long-term survival occurred when the tumors exceeded
TABLE 1. Cox regression analysis
Univariate Cox regression
Factor N P value* HR 95% CI
Tumor depth
No submucosa 64 1.00
Submucosa involved 69 .005 4.19 1.55–11.33
Tumor length
Continuous variable 133 <.001 1.51 1.22–1.87
Tumor length <.001
0–1 cm (reference) 70 1.00
>1–2 cm 33 .37 1.65 0.45–4.92
>2–3 cm 15 .20 2.43 0.65–9.50
>3 cm 15 .001 9.00 3.2–25.1
Tumor length
3 cm (reference) 118 1.00
>3 cm 15 <.001 6.69 2.81–15.89
Nodal status
N0 (reference) 114 1.00
N1 19 .02 3.25 1.25–8.45
LVI status2
No (reference) 102 1.00
Yes 23 .01 3.42 1.29–9.06
Grade
Well/moderately
differentiated
(reference)
93 1.00
Poor/undifferentiated 34 .02 2.71 1.19–6.18
Barrett esophagus
No (reference) 12 1.00
Yes 121 .83 1.18 0.27–5.07
LVI, Lymphatic/vascular invasion. *P< .05 accepted as statistically significant.rgery c October 2009
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to<2 cm ¼ 166 months, 2 cm to<3 cm ¼ 97 months,>3
cm ¼ 67 months; P< .001) . Additionally, a categorical as-
sessment of tumors that were 3 cm or less in length com-
pared against patients with tumors greater than 3 cm
(Table 4 and Figure 2) suggested that this cutoff identified
a significant drop-off in long-term survival. The 3- and 5-
year survivals for patients with tumors 3 cm or less were
93% and 85%, respectively, compared with 3- and 5-year
survivals for patients with tumors of more than 3 cm of
46% and 34% (P< .01). Lymph node involvement and
LVI was also more likely in patients with tumors greater
than 3 cm in length (47% and 54%, respectively) versus pa-
tients with tumors 3 cm or less (10% and 14%, respectively)
(P< .01). Survival in patients without lymph node metasta-
ses was worse in patients with tumors greater than 3 cm (N0,
>3 cm median survival 30 months vs 204 months if N0, 3
cm; P<.01). There was also a trend to decreased survival in
the subset of node-positive patients with larger tumors (N1,
>3 cm median survival not reached vs 21.3 months for N1,
 3 cm; P¼ .1). The small number of patients with intramu-
cosal involvement (3 patients) and greater than 3 cm esoph-
ageal length makes more detailed analysis difficult with this
small sample size.
Tumor length was also significantly associated with dis-
ease-free survival, with tumors less than 3 cm having a dis-
ease-free survival of 218 months versus 94 months for
tumors greater than 3 cm (P< .001). Disease-free survival
TABLE 2. Demographics
Demographics No. (%)
Patients 133
Gender
Male 118 (89%)
Female 15 (11%)
Age, y (median, range) 63 (26–83)
Race
White 124 (93%)
Hispanic 8 (6%)
African American 1 (1%)
Location
Upper/middle 10 (8%)
Lower/GEJ 123 (92%)
Type of esophageal resection
ILE 57 (43%)
THE 63 (47%)
Three field 7 (5%)
MIE 6 (5%)
pT1 subsets
No submucosal involvement and  3 cm in length 61 (52%)
No submucosal involvement and>3 cm in length 3 (2%)
Submucosal involvement and  3 cm in length 57 (48%)
Submucosal involvement and>3 cm in length 12 (9%)
GEJ, Gastroesophageal junction; ILE, Ivor Lewis esophagectomy; THE, transhiatal
esophagectomy; MIE, minimally invasive esophgectomy.The Journal of Thoracic and Calso correlated with esophageal length when tumor length
was evaluated as a continuous variable (HR 1.49 [1.21–
1.84]; P< .001) or with a categorical cutoff of 3 cm (HR
6.1, CI 2.6–14.3; P< .001). The locoregional recurrence
was more frequent in tumors greater than 3 cm (4/15 pa-
tients, 27%) than in those that were 3 cm or less (2/118 pa-
tients, 2%; P ¼ .001). Distant recurrence was also more
frequent in tumors greater than 3 cm (20%) than in those
3 cm or less (5/118 patients, 4%; P< .05).
TABLE 3. Pathologic features
Pathologic factor No. (%)
Tumor depth
No submucosal involvement 64 (48%)
Submucosal involvement 69 (52%)
Tumor length
0–1 cm 70 (53%)
>1–2 cm 33 (25%)
>2–3 cm 15 (11%)
>3 cm 15 (11%)
Nodal status
N0 114 (86%)
N1 19 (14%)
LVI status
No 102 (77%)
Yes 23 (17%)
Missing 8 (6%)
Grade
Well/moderately differentiated 93 (70%)
Poor/undifferentiated 34 (26%)
Missing 6 (5%)
Barrett esophagus
Yes 121 (91%)
No 12 (9%)
LVI, Lymphatic/vascular invasion.
FIGURE 1. Histogram distribution of esophageal tumor lengths.ardiovascular Surgery c Volume 138, Number 4 833
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As noted by other authors, tumor depth also correlated
with long-term outcome in patients with pT1 disease.8,9
The 3- and 5-year survivals were significantly improved in
patients without submucosal involvement (100% and
90%, respectively) compared with those with submucosal
involvement (77% and 69%; P<.01, Table 4 and Figure 3).
Patients with submucosal involvement were also signifi-
cantly more likely to have positive lymph nodes (23% vs
5%) and LVI (29% vs 7%) than were patients without sub-
mucosal involvement (P< .01 and P< .01, respectively).
The combination of tumor length greater than 3 cm and sub-
mucosal involvement identified a higher risk group of pT1
patients than did submucosal involvement alone (5 years:
22% vs 69%; P<. 01).
Analysis by Proposed Revised T Classification
The disease was clinically staged with endoscopy (133
patients), endoscopic ultrasound (85 patients), CT scan
(121 patients), and PET scan (58 patients). The clinical stage
before resection was stage 0 (7 patients), stage I (78 pa-
tients), stage IIA/B (43 patients), stage III (2 patients), and
incomplete stage (2 patients). All patients except 2 had R0
resections (2 positive proximal margins), and only 2 patients
received adjuvant therapy. Assessment of outcome, when
we added tumor length to submucosal involvement, demon-
strated the potential relevance of our previously defined
3-cm esophageal tumor length cutoff and submucosal in-
volvement in pT1 esophageal adenocarcinoma (Table 4
and Figure 4). One of the limitations of this study is indeed
the small sample size. As an example, the subset of patients
with intramucosal tumors greater than 3 cm and lymph node
metastases was too small to perform a meaningful analysis
(3 patients). Additionally only 2 patients had intramucosal
tumors that are greater than 3 cm and node-negative disease.
These small numbers make determining the true variable
TABLE 4. Outcome according to tumor depth, tumor length, and risk
factor group
Five-year
survival
% LN
positive
% LVI
positive
Tumor depth
No submucosa (n ¼ 64) 90% 5% 7%
Submucosa (n ¼ 69) 69%z 23%z 29%z
Tumor length
3 cm (n ¼ 118) 85% 10% 14%
>3 cm (n ¼ 15) 34%z 47%z 54%z
pT1 subgroups*
Group 1 (reference) (n ¼ 61) 90% 3% 7%
Group 2 (n ¼ 60) 81%y 18%z 21%z
Group 3 (n ¼ 12) 22%z 50%z 70%z
LN, Lymph node; LVI, lymphatic/vascular invasion. *pT1 subgroups: group 1, no sub-
mucosal involvement and tumor length  3 cm; group 2, submucosal involvement or
tumor length>3 cm; group 3, submucosal involvement and tumor length>3 cm. yP<
.05. zP< .01.834 The Journal of Thoracic and Cardiovascular Surresponsible for decreased long-term survival difficult (ie, tu-
mor length vs depth) and emphasize the fact that this study is
only exploratory and will require a larger, prospective study
in the future to validate and to confirm the proper cutoff
point.
Univariate and Multivariate Analysis
Univariate analysis was performed by the Cox regression
method (Table 1). We observed no survival difference when
we looked at the type of surgical resection performed (ie,
transhiatal esophagectomy vs Ivor Lewis esophagectomy
and 3-field esophagectomy [HR: 0.48, 1.00, and 1.22,
respectively; P ¼ .4]), even when subsetted according to
tumor length (>3 cm, P ¼ .1; 3 cm, P ¼ .6). The unad-
justed hazard ratio for esophageal tumor length with a cutoff
of 3 cm was 6.69 (CI 2.81–15.89; P< .001). The only
FIGURE 2. Survival curve based on tumor length (P< .001, 95% CI):
3 cm, n ¼ 118;>3 cm, n ¼ 15; P< .001.
FIGURE 3. Survival curve based on tumor depth (95% CI): no submuco-
sal involvement, n ¼ 64; submucosal involvement, n ¼ 69; P ¼ .002.gery c October 2009
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the presence of Barrett dysplasia.
We then performed a multivariable Cox proportional haz-
ard regression model of all variables from Table 4 with a P
value of .25 or less and esophageal length with a cutoff of 3
cm or multiple cutoff points, as noted in Table 4. According
to the Wald stepwise selection with P ¼ .10 as entry and re-
moval probability, the final model for a 3-cm cutoff (>3 cm,
adjusted HR 5.5, CI 2.09–14.46; P ¼ .001) or multiple cut-
off points was significant (P¼ .007). The only other variable
significant by this process was tumor depth (submucosal in-
volvement: HR 3.17, CI 1.08–9.25; P ¼ .35).
DISCUSSION
Several investigators have evaluated tumor length as a pre-
dictor of survival in patients with esophageal carcinoma dur-
ing the past 10 years.4-6,10,11 One study, by Eloubeidi and
associates6 in 2002, based on data from the National Cancer
Institute Surveillance Epidemiology End Results database,
found that tumor length greater than 3 cm was associated
with decreased overall survival when compared with shorter
tumors. In this study, a significant portion of the patients
(43.8%) did not have tumor length recorded, and therefore
it could not be used in the calculations. A consistent method
of tumor length measurement was also not used in the study,
so that it is difficult to make firm conclusions. A second
study from Germany, by Bollschweiler and associates4 in
2006, examined the impact of tumor length on survival.
They looked at tumors longer than 3 cm and found on uni-
variate analysis that patients with tumors of 3 cm or less
had a better 5-year survival than patients who had tumors
that were longer than 3 cm. On multivariate analysis, how-
FIGURE 4. Survival based on number of risk factors in patients with pT1
esophageal adenocarcinoma (95% CI): RF 0, no submucosal involvement
and tumor length  3 cm, n ¼ 61; RF 1, submucosal involvement or tumor
length>3 cm, n¼ 60; P¼ .026; RF 2, submucosal involvement and tumor
length>3 cm, n ¼ 12; P< .001.The Journal of Thoracic and Cever, they found that there was no difference in survival
based on tumor length. A third study from Japan, by Tachi-
bana and colleagues10 in 1999, evaluated 129 patients with
squamous cell carcinoma and found that tumor length was
not an independent predictor for survival in patients with
squamous cell carcinoma of the esophagus. Recently, Al-
torki and coworkers11 looked at patients with early (pT1)
esophageal carcinoma and found that patients with longer
tumors as well as patients with submucosal involvement
had a decreased 5-year survival and were more likely to
have multifocal disease. They concluded that patients with
submucosal involvement were not good candidates for non-
surgical management because of potential lymph node in-
volvement and decreased long-term survival.
Our group7 has previously demonstrated that esophageal
tumor length is an important predictive factor in a group
of patients with more advanced esophageal cancer. In this
previous study, 3 cm was used as a cutoff point because it
was the median size of the population and this was the
size at which an asymptote occurred. In this current article,
we attempted to determine whether this previously deter-
mined cutoff point (3 cm) was also applicable in earlier
pT1 esophageal adenocarcinoma. We excluded all patients
with neoadjuvant treatment to avoid treatment effects in
the analysis. Using these criteria, we were able to show
that tumor length greater than 3 cm is indeed a predictor
of survival for patients with pT1 esophageal adenocarci-
noma. The 5-year survival for patients with tumors greater
than 3 cm was 34% compared with 85% for patients with
tumors of 3 cm or less. We also found that patients with tu-
mors greater than 3 cm were more likely to have positive
lymph nodes and LVI in the pathologic specimens. Impor-
tantly, even when controlling for lymph node status and
LVI, which are known to portend a bad prognosis,9,12-15 tu-
mor length was still a predictor of survival in our patients.
Limitations of this study include the fact that this is a small
dataset at a single institution and validation of this prognos-
tic factor will require a larger prospective data set from other
institutions. Another limitation of this study is that 3 cm was
selected as a cutoff from previous work by our group in more
advanced tumors.7 Future studies may find that there is
a more optimal cutoff point for earlier stage tumors and, as
with patients who have lung cancer, there may indeed be
several important esophageal length cutoff points.
We also examined our data to see whether the addition of
tumor length to an established T1 prognostic factor (submu-
cosal involvement) could identify a high-risk group of pa-
tients with pT1 esophageal adenocarcinoma.8,14 We found
that when patients were stratified into new pT1 subgroups
there was a significant difference in survival among patients
in groups 1, 2, and 3 (Table 4). Patients with tumors of 3 cm
or less and no submucosal involvement (group 1) had a 5-
year survival of 90%, whereas patients in group 2 (tumors
>3 cm or submucosal involvement) had a 5-year survivalardiovascular Surgery c Volume 138, Number 4 835
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and submucosal involvement (group 3) had a 5-year survival
of 22%. Patients in group 3 were also at significantly higher
risk of lymph node involvement, suggesting that patients in
this group may not be ideal candidates for nonsurgical abla-
tive or endoscopic mucosal resection techniques.
As previously mentioned, there are significant limitations
within our study, and over-interpretation of the data should
be avoided. First, this is a retrospective study that is limited
by the data that were available for analysis at a single insti-
tution. The study population was only 133 patients, which
leaves some groups small in the statistical analyses. We
chose to use a cutoff point of 3 cm because of work in our
prior study with predominantly more advanced tumors.7 Fu-
ture studies may reveal that there are other cutoff points that
are more applicable for early-stage tumors and later-stage
tumors. This study simply demonstrated that the previous
3-cm cutoff was also predictive in pT1 esophageal adenocar-
cinoma. It is also important to recognize that the study pop-
ulation was limited to patients with adenocarcinoma and
may not apply to patients with other types of esophageal car-
cinoma, such as squamous cell carcinoma.
In summary, this study should not be over-interpreted and
will require validation in other larger data sets. This study
should be viewed as an exploratory study that suggests that
esophageal tumor lengthmay be a predictor of long-term sur-
vival in patients with pT1 esophageal adenocarcinoma. In
combination with submucosal involvement, esophageal tu-
mor length (>3 cm) identifies a group of patients with pT1
disease who are at high risk for lymph node involvement
and decreased long-term survival. Prospective studies need
to be performed in the future to confirm the significance of
esophageal tumor length in pT1 esophageal adenocarcinoma
and its potential ability to identify high-risk patients for adju-
vant therapy and more extensive lymphadenectomy.836 The Journal of Thoracic and Cardiovascular SurReferences
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